Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer

Introduction: The effect of systemic administration of bevacizumab in cancer patients over a 5-year period after the beginning of chemotherapy treatment and comparison with a control group. Methods: The study population consists of adult patients with metastatic breast or colorectal cancer who had n...

Full description

Bibliographic Details

Published in:	Hellenic Journal of Cardiology
Main Authors:	Ioannis Kapelakis, Konstantinos Toutouzas, Maria Drakopoulou, Archontoula Michelongona, Flora Zagouri, Aristotle Mpamias, Paraskevi Pliatsika, Meletios-Athanasios Dimopoulos, Christodoulos Stefanadis, Dimitrios Tousoulis
Format:	Article
Language:	English
Published:	Elsevier 2017-05-01
Subjects:	Bevacizumab Angiogenesis Cancer Coronary artery disease Vascular endothelial growth factor
Online Access:	http://www.sciencedirect.com/science/article/pii/S1109966616302366